ABSTRACT
INTRODUCTION
The short chain fatty acid butyrate is produced by bacterial fermentation of fiber and represents a primary energy source for normal colonic epithelial cells. Withdrawal of butyrate induces apoptosis, demonstrating that it acts as a survival factor for normal colonic epithelial cells (1, 2) . In contrast, in colonic carcinoma cells butyrate induces G1 or G2 arrest, followed by differentiation and apoptosis (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) , suggesting that the butyrate-induced signaling is different in normal epithelium and cancer tissues. Butyrate inhibits proliferation of transformed epithelial cells through upregulation of p21 and downregulation of c-Myc, however the mechanisms whereby butyrate supports survival and promotes proliferation of normal epithelial cells are less well understood. These divergent effects of butyrate are known as the "butyrate paradox". The availability of alternative energy sources and different metabolic activities of normal and transformed cells have been proposed to underlie the divergent effects of butyrate (3) , but a molecular mechanisms that could account for the conflicting effects of this short chain fatty acid on normal and transformed colonic epithelial cells have not been determined. In this study we examined whether genetic and epigenetic changes associated with colon cancer regulate the responsiveness of cells to butyrate.
Inactivation of the tumor suppressor genes APC and p53 and activation of the oncogene kras underlie the development of the majority of colorectal cancers (11) . The mutational activation of k-ras, or its downstream signaling effectors, is present in up to 50% of sporadic colorectal tumors (11, 12) . The majority of the k-ras mutations are gain-of-function mutations at codon 12 and 13 and an activated k-ras has been shown to cooperate with both mutant Apc and mutant p53 in the transformation of colonic epithelial cells (13, 14) . Recent data suggest that mutations in k-ras may be sufficient to initiate colon tumor development (15) . Accordingly, targeted expression of oncogenic k-ras in intestinal cells resulted in development of intestinal tumors in mice in the absence of detectable inactivating mutations of the tumor suppressor gene Apc (16) . Signaling transmitted through Ras results in activation of several downstream effectors, with the MAPK/ ERK1/ERK2 and the PI3K/AKT pathways playing a crucial role in modulation of the k-ras target genes which in turn regulate processes such as proliferation, differentiation and apoptosis (17) (18) (19) (20) . Regulation of cell survival by Ras is complex, complicated by the fact that activation of Ras, like several other oncogenes, can induce both pro-and anti-apoptotic signaling. Ras protects from apoptosis via PI3K/AKT/Rac and NF-κB signaling, and promotes apoptosis through its effectors RASSF1/Nore1/Mst1 (21) . Raf/MEK/ERK signaling can be either anti-or pro-apoptotic, but the understanding of the downstream targets of Ras that mediate its effect on apoptosis is still far from complete.
To determine the role of activated k-ras in butyrate-induced apoptosis and to identify its downstream targets, we used the HCT116 colorectal carcinoma cell line and two clones derived form HCT116 cells with a targeted inactivation of the activated k-ras allele, Hkh2 and Hke-3. HKh2 and Hke-3 cells are morphologically altered, do not form colonies in soft agar and fail to form tumors in nude mice (22) , demonstrating that tumorigenicity of HCT116 cells directly depends on the presence of an activated kras allele.
In this study we showed that oncogenic activation of a k-ras allele is sufficient to sensitize cells to butyrate-induced apoptosis and that this is, at least in part, mediated through transcriptional downregulation of gelsolin expression. Gelsolin is a member of a large family of actin severing and capping proteins (23). In addition, human gelsolin has been shown to inhibit apoptosis through its ability to block mitochondrial membrane potential and to inhibit caspase activity (24) (25) (26) (27) (28) (29) (30) (31) . The role of gelsolin in apoptosis is complicated by the fact that gelsolin is also a substrate for caspase-3, caspase-7 and caspase-9 (28, 29) , which cleave gelsolin between Asp 352 and Gly353, and generate an N-terminal cleaved product with pro-apoptotic activity (26) . The anti-apoptotic activity of gelsolin resides in its Cterminus and apparently counteracts the pro-apoptotic activity of the N-terminal domain (30) .
Overexpression of gelsolin has been shown to reverse transformation of Ras-transformed cells (32, 33) , pointing to potential tumor suppressive properties of gelsolin. Although no mutations of gelsolin have been described in human cancers, its expression is reduced or absent in approximately 60-90 % of human colon, breast, bladder, prostate, and stomach cancers (24, (34) (35) (36) (37) (38) (39) .
Our data demonstrate that Ras mutations may underlie the frequent down-regulation of gelsolin in primary colon cancers (40) . In addition, our finding that activating mutations of k-ras or silencing of gelsolin sensitize cells to butyrate-induced apoptosis, provides a mechanism for the divergent effects of butyrate on normal and transformed epithelial cells.
MATERIAL AND METHODS

Cell lines, reporter gene assay and transfections
The HCT116 human cell line was derived from colorectal carcinoma and harbors an activating mutation in codon 13 of the k-ras protooncogene. Two isogenic clones of the HCT116 cells with a disrupted mutant k-ras allele, Hkh2 and Hke-3, were generated by homologous recombination (22 Gelsolin expression was silenced using a pool of four siRNAs directed aginst the coding region of gelsolin (Dharmacon, Lafayette, CO). Cells were transiently transfected with 5-100 nM of gelsolin siRNA using Ca-phosphate method as described above. Immunoblotting was performed using standard procedures (41) . Antibodies specific for gelsolin were obtained from Sigma, and antibodies recognizing cleaved PARP, caspase-9 and caspase-7 were purchased from Cell signaling Technology (Beverly, MA).
cDNA microarrays
We performed cDNA-microarray analysis using microarray slides comprising 8063 cloned sequences produced by the Microarray facility at the Albert Einstein College of Medicine. Total RNA was isolated using the RNeasy Midi kit (Quiagen) as suggested by the manufacturer. 100
µg of RNA from HCT116 cells was labeled with Cy3 (channel 1) and RNA from Hke-3 or Hkh2 cells with Cy5 (channel 2) fluorescent dye. After hybridization and washing (42) , slides were scanned (532nm/ Cy3 and 633nm/Cy5), the two images were superimposed, and quantified using Scanalyze 1.41 software. Data were imported into an Access database for further analysis. and Hkh2/Hke-3 cells was greater than 1.5 (k-ras upregulated genes) or less than 0.6 (k-ras downregulated genes).
Apoptosis
Adherent and floating cells were collected and resuspended in hypotonic buffer (0.1% Triton X-100, 0.1% sodium citrate) and stained with Propidium iodide (50 µg/ml) for 4 hours at 4 o C.
Samples were filtered through a nylon mesh (40 micron pore-size) and analyzed by flow cytometry. Cell cycle distribution, and the extent of apoptosis (cells with a subG1 DNA content)
were analyzed by the Modfit software.
Immunofluorescence.
Cells were grown on chamber slides, and were either left untreated or were treated with 
RESULTS
Activating mutations of K-ras sensitize epithelial cells to apoptosis
The HCT116 colorectal cancer cell line harbors an activating mutation in the k-ras protooncogene. Two clones, Hkh2 and Hke-3, were derived from HCT116 cells by the targeted deletion of the activated k-ras allele and both clones displayed loss of tumorigenicity in vitro and in vivo (22) . We used these isogenic cell lines to examine whether k-ras mutations modulate the response to butyrate, a dietary chemopreventive agent which exerts different biological activity in normal and transformed epithelial cells. Isogenic cell lines were treated with 3 mM Na-Bu for 24, Ras is sufficient to confer resistance to Na-Bu-induced apoptosis. We showed that HCT116 cells were also sensitized to apoptosis induced by SAHA, another HDAC inhibitor (Fig. 1B) , and to 5FU-induced apoptosis (manuscript in preparation), demonstrating that the increased sensitivity of HCT116 cells to apoptosis is not restricted to butyrate.
To further determine whether inactivation of the ras signaling pathway alter the responsiveness of cells to butyrate, we tested the effect of apigenin on butyrate-induced apoptosis. Apigenin is a dietary flavonoid which has been shown to reverse transformation of cells via inhibition of the MAPK kinase activity, a downstream effector of the ras activated signaling pathway (43) (44) (45) . We demonstrated that apigenin inhibited butyrate-induced apoptosis in HCT116 cells in a dose-dependent manner ( Fig. 2A and 2B ). The extent of apoptosis in parental HCT116 cells treated with butyrate and 20µM apigenin was reduced to levels comparable to those of butyrate-induced apoptosis in Hkh2 and Hke-3 cells ( Fig. 2A and 2B ). In contrast, apigenin did not have a significant effect on butyrate-induced apoptosis in Hkh2 and
Hke-3 cells. The data in Fig. 1-2 suggest that the acquisition of a k-ras mutation confers upon colon cells the ability to respond to the physiological regulator of homeostasis, butyrate, by undergoing apoptosis. Conversely, reversal of k-ras mediated transformation by genetic inactivation of the mutant k-ras allele, or pharmacological inhibition of ras signaling is sufficient to protect cells from butyrate-induced apoptosis.
These data therefore established a basis for the differential response of normal and cancer cells to butyrate.
Activating mutation of k-ras modulates the expression of genes involved in apoptosis, including gelsolin
To define the pathway whereby k-ras signaling promotes butyrate-induced apoptosis, we performed cDNA-microarray analysis on the isogenic cell lines that differ by the presence of the mutant k-ras. We considered sequences as potential k-ras target genes if the ratio of the signals between HCT116 and Hkh2 or Hke-3 cells was greater than 1.5 (k-ras upregulated genes) or less than 0.6 (k-ras downregulated genes). We identified several sequences that are differentially expressed in HCT116 cells compared to the two clones with a disrupted mutant k-ras allele, among them several known k-ras target genes, such as epiregulin (46) , glucose transporter (47), fibronectin (17) , and VEGF (48) (data not shown). In addition, we demonstrated that a family of IFN responsive genes is negatively regulated by Ras signaling through Ras-mediated inhibiton of STAT1/STAT2 expression (49) .
Analysis of the Ras target genes revealed that several genes that modulate apoptosis were also regulated by k-ras signaling (Fig. 3) . Bag-1, an anti-apoptotic member of the BCL-2 family (50) and gelsolin, an actin binding protein (23) were downregulated by an activated k-ras. In contrast, the expression of NIP1, NIP2 and NIP3, a family of proapoptotic proteins, was upregulated in cells containing the activating k-ras mutation. NIP proteins bear a limited homology to the BCL-2 homology domain 3 (BH3), and regulate apoptosis by interacting with BCL-2 and BCL-x (51) (52). Another gene upregulated by oncogenic k-ras was PHLDA1
(Pleckstrin Homology Like Domain, family A) which is a human homologue of the mouse gene TDAG51, which plays a crucial role in activation-induced apoptosis of T cells (53) . Activation of NIP3 expression by k-ras has been recently demonstrated in fibroblasts (17) , however gelsolin, Bag-1, NIP, NIP2, and PHLDA1 represent potentially novel target genes of activated k-ras.
These data demonstrated that genes with known pro-apoptotic functions, such as NIP1, NIP2, NIP3, and PHLDA1, are upregulated by activated k-ras, whereas k-ras signaling leads to inhibition of genes with an anti-apoptotic function, such as Bag-1 and gelsolin. Such changes may underlie the increased susceptibility of HCT116 cells to butyrate, compared to Hkh2 and Hke3 cells.
The fact that oncogenic activation of Ras inhibited gelsolin expression was of particular interest to us, because the expression of gelsolin is known to be reduced or lost in colon cancer (40) . To determine whether oncogenic Ras inhibits gelsolin expression at the transcriptional level we transfected HKe-3 cells with several deletion mutants of the gelsolin promoter fused to the luciferase reporter gene (54) . Five different deletion constructs of the gelsolin promoter (Fig. 4A) were transfected into Hke-3 cells together with an empty vector, or with a plasmid directing the expression of mutant Ras. The luciferase activity of the chimeric constructs was compared to the activity of the empty plasmid pGL-3 basic.
We showed that the activities of the full length gelsolin promoter (-2524/LUC1) and the -872/LUC3 deletion construct were markedly downregulated by mutant Ras (Fig. 4B) , demonstrating that Ras signaling inhibits the expression of gelsolin at the transcriptional level. In contrast, the activities of the LUC-5 (-167) and LUC 7 (-109) were not significantly affected by the mutant Ras, suggesting that the major element(s) responsible for the negative regulation of gelsolin promoter by RasV12 is located in the region between -167 and -872.
Our data therefore suggest that k-ras activation is sufficient for the inhibition of gelsolin expression, underlying the frequently reduced gelsolin expression in cancer cell lines and primary tumors (23,34-40).
We next examined whether the levels of gelsolin protein are also reduced in cells harboring an activated k-ras allele. We showed that the constitutive expression of gelsolin (0, Fig. 5A ) was low in Consistently, we demonstrated that butyrate activates gelsolin promoter activity in both HCT116 and
Hke-3 cells, and that the -109 region of the gelsolin promoter appears to be sufficient to confer the inducibility by butyrate (Fig. 5B) .
Butyrate induces apoptosis, at least in part, through the activation of caspase-3 (55,56), a caspase that has been shown to cleave gelsolin (26) and generates a cleaved product of gelsolin with proapoptotic activity. We did not detect significant activation of caspase-3 in HCT116, Hkh2 or Hke-3 cells upon butyrate treatment, suggesting that in these cells butyrate induces apoptosis in a caspase-3 independent manner. Likewise, butyrate treatment did not induce significant cleavage of gelsolin (not shown).
Silencing of gelsolin expression promotes butyrate-induced apoptosis
What is the role of gelsolin in butyrate-induced apoptosis? Overexpression of proteins often yields ambiguous results, in particular in the case of gelsolin because overexpression of full length protein also leads to an increased amount of cleaved gelsolin product upon apoptotic insult (57) . To avoid difficulties with ascribing the biological outcome to the increased levels of full length protein or to the increased amounts of the cleaved product, we pursued the role of gelsolin in apoptosis by silencing its expression through siRNA. Hke-3 cells were transfected with a pool of four RNA duplexes directed against the coding region of gelsolin as described in Material and Methods. Cells were transfected with 25 or 50 nM siRNA and the expression of gelsolin protein was examined 48 and 96 hours after transfection in both untreated cells and in cells treated with 3mM butyrate for 24 hours. As shown in (Fig. 6B) , demonstrating the specificity of gelsolin siRNA.
We next examined whether silencing of gelsolin expression in HKe-3 cells modulates butyrateinduced apoptosis. The parental Hke-3 cells and Hke-3/gelsolin siRNA cells were treated with 3mM butyrate for 48 hours and the extent of apoptosis was determined by PI staining (Fig. 6C) . As shown earlier, Hke-3 cells are, due to the deletion of the mutant Ras, relatively resistant to butyrate-induced apoptosis. Silencing of gelsolin expression strongly enhanced butyrate induced apoptosis demonstrating that full length gelsolin inhibits butyrate-induced apoptosis. In addition, these data suggested that oncogenic Ras promotes butyrate induced apoptosis at least in part through transcriptional inhibition of gelsolin expression ( Fig. 3 and 4) .
How does gelsolin interfere with butyrate-induced apoptosis? Gelsolin has been shown, through its ability to associate with VDAC (voltage dependent anion channel), to regulate mitochondrial permeability for cytochrome and thereby to modulate the cascade of caspase activation (27) (28) (29) . Our experimental system of silenced gelsolin expression allowed us to test the hypothesis that the activity of caspases is increased in the absence of gelsolin. Hke-3 cells were either mock transfected or transfected with 25 or 50 nM gelsolin siRNA and treated with 3mM butyrate for 24 or 48 hours as indicated in Fig. 7 . The expression of gelsolin, activation of caspase-9 (assessed by the appearance of the cleaved product), activation of caspase-7 (assessed by the disappearance of full length caspase 7) and the cleavage of PARP, a caspase substrate, were determined by immunoblotting. Both concentrations of siRNA were sufficient to silence constitutive and induced gelsolin expression (Fig. 7) .
We did not detect the activation of caspase 9, caspase-7 ( Fig. 7) , or caspase 3 (not shown) in cells treated with butyrate for 24 hours. In contrast, the cleavage of PARP was apparent as early as 24 hours after treatment with butyrate, and it occurred predominantly in cells with silenced gelsolin expression. 48 hours after treatment of cells with butyrate, we demonstrated both activation of caspase-9 and caspase -7 almost exclusively in cells with silenced gelsolin expression. Accordingly, the levels of cleaved PARP were significantly increased in gelsolin deficient cells (Fig. 7) . These data demonstrated that silencing of gelsolin expression promotes butyrate-induced apoptosis through amplification of the activation of caspase 9 and caspase-7, which is in agreement with reports that full length gelsolin inhibits the activation of caspases (28, 29) .
Overexpression of full length gelsolin in HCT116 did not confer significant protection from butyrateinduced apoptosis, most likely due to the presence of the cleaved product of gelsolin in these cells, which exerts pro-apoptotic activity and overcomes the anti-apoptotic activity of full length gelsolin (Supplemental Fig. 1A and 1B) . In contrast, overexpression of gelsolin in Caco-2 cells did not result in detectable cleavage of gelsolin upon butyrate treatment and thereby protected cells from butyrateinduced apoptosis (Supplemental Fig. 2 ). The level of protection was comparable to the protection conferred by BCL-2. In accordance, expression of gelsolin in the antisense direction sensitized Caco-2 cells to both butyrate and sulindac-induced apoptosis (Supplemental Fig. 2 ), confirming the antiapoptotic nature of gelsolin.
Silencing of gelsolin promotes sulindac induced apoptosis
Next we determined whether gelsolin regulates apoptosis also in response to the pharmacological 
DISCUSSION
The response of normal and transformed epithelial cells to the short chain fatty acid, butyrate, is divergent: butyrate serves as an energy source for normal epithelial cells and supports their survival and proliferation, but it induces a rapid growth arrest, coupled to differentiation and apoptosis in transformed cells. This observation is known as the butyrate paradox, but the mechanisms underlying the divergent action of butyrate are not understood.
To determine whether genetic alterations associated with colon cancer modulate the responsiveness to butyrate, we used isogenic cell lines derived from the HCT116 cell line that differ only by the presence of oncogenic k-ras or p53. Targeted deletion of p53 in HCT116 did not alter the response of cells to butyrate (data not shown), which is in accord with published data demonstrating that butyrate induces growth arrest and apoptosis in a p53-independent manner (6). In contrast, this study demonstrates that targeted deletion of an oncogenic k-ras is sufficient to protect cells from butyrate-induced apoptosis. In agreement, we showed that apigenin, an inhibitor of ras signaling and ras dependent transformation, inhibits the ability of butyrate to elicit the apoptotic response in HCT116 cells. These results demonstrate that during the process of cellular transformation cells acquire the ability to respond to butyrate by undergoing apoptosis.
Apigenin inhibits MAPK activation, raising the possibility that activation of the MAPK pathway may be required for the pro-apoptotic activity of butyrate. Consistent with this hypothesis is the finding that during spontaneous differentiation of Caco-2 cells, which is accompanied by downregulation of the MAPK activity (58), the cells become resistant to butyrate-induced apoptosis (data not shown) and (59) .
The expression of the oncogenic Ras induces both pro-and anti-apoptotic signaling. When we compared the sensitivity of the isogenic cell lines to a variety of apoptosis-inducing agents, we found that HCT116 cells, harboring mutant Ras, are also more sensitive to apoptosis induced by chemotherapeutic agents, such as 5-fluorouracil and to growth factor-withdrawal induced apoptosis, than the two clones with the targeted deletion of the mutant Ras allele (not shown). In contrast, we showed that HCT116 are less sensitive to apoptosis induced by TGFbeta (data not shown), most likely due to a negative regulation of Smad signaling by oncogenic Ras (60).
Expression of oncogenic k-ras has recently been shown to enhance apoptosis of embryonic stem cells in response to chemotherapeutic agents (61) , and the expression of an activated k-ras in Caco-2 cells resulted in accelerated apoptosis in response to sulindac (62) . Thus, K-ras is a member of the group of proto-oncogenes whose activation can induce not only proliferation, but also apoptosis. Several other oncogenes, such as c-myc, ras, E1A, E2F-1, CDC25A have also been shown to be dual function proteins-they induce both cell proliferation and apoptosis (63) (64) (65) (66) (67) (68) .
Pro-apoptotic activity of activated oncogenes may in fact represent the primary cause of elimination of mutant cells, and may explain the fortunate fact that cancer is a rare disease. In We demonstrated that activation of K-ras modulates the expression of several genes involved in apoptosis. One of the genes that was strongly downregulated by oncogenic k-ras was gelsolin, an actin binding protein with an established role in apoptosis (26, 30, 57, 71) . This is consistent with a report that full length gelsolin inhibits activation of caspase-3, caspase-8
and caspase-9 due to the lack of release of cytochrome c in cells overexpressing gelsolin (28, 29) .
Our data, however, revealed that full length gelsolin had no major affect on apoptosis in HCT1116 cells. The lack of the protective effect of full length gelsolin is likely due to its cleavage in cells that overexpress gelsolin (Supplemental Fig. 1A and 1B) . Consistent with this, we showed that the expression of the N-terminal cleavage product exerts strong pro-apopotic activity in HCT116 cells (not shown). It is therefore likely that the regulation of apoptosis by gelsolin depends on its caspase-mediated processing, and that the ratio between the full length and the cleaved product of gelsolin determines whether the cell will undergo apoptosis or survive. The expression of gelsolin is activated during differentiation of Caco-2 cells (data not shown), a process accompanied by acquired resistance to butyrate (data not shown, (59)). Likewise, overexpression of gelsolin in Caco-2 cells conferred significant protection from butyrate-induced apoptosis (Supplemental Fig. 2 ). It is possible that accumulation of gelsolin is, at least in part, responsible for the resistance of differentiated cells to butyrate.
The significance of gelsolin downregulation for the progression of colon cancer remains to be determined. Because oncogenic k-ras has been shown to synergize with an Apc mutation in the progression of colon cancer (13), we have generated a compound mouse model, containing both an Apc 1638 mutation and a gelsolin null mutation, to test the hypothesis that gelsolin is a downstream effector of k-ras signaling in the progression of colon cancer. Our preliminary data suggest that targeted deletion of gelsolin in vivo, like oncogenic k-ras, enhances Apc-initiated development of intestinal tumors (Klampfer, manuscript in preparation). Our data also suggest that gelsolin might have prognostic value in colon cancer patients. We demonstrated that 
